TrevogrumabCheck methods and identity
How animal studies tested muscle and fat during weight change
2 numbered sourcesSource years 2024–2026
Peptides are short amino-acid chains joined by peptide bonds. Some can activate receptors, while larger antibodies can be engineered to block a particular protein. Trevogrumab is an investigational monoclonal antibody that blocks myostatin. An older study in male mice and nonhuman primates examined what happened to lean tissue and fat when investigators blocked myostatin and activin A during treatment with a GLP-1 receptor agonist. [1]
The researchers compared several experimental groups. They examined the response to a GLP-1 receptor agonist and to adding antibodies directed against the two proteins that help regulate muscle size. This allowed them to compare total weight with separate measurements of fat and lean mass. In the animal experiments, combined blockade helped preserve muscle-related measures and was associated with a larger reduction in fat under the tested conditions. [1]
In the primate work, the researchers studied trevogrumab and garetosmab, the antibody directed against activin A, with semaglutide. The two antibodies target different signals. An outcome from a group receiving both cannot isolate the effect of trevogrumab unless the other treatment groups provide the appropriate comparison. The exact antibody and GLP-1 receptor agonist used also matter when comparing the mouse and primate experiments. [1]
The older animal work helped motivate questions for human trials, including whether changes in tissue composition could be measured alongside changes in body weight. Its findings concern animal models and specified experimental regimens. Human participants can provide a direct clinical comparison when assigned to the relevant treatments. A result involving both antibodies and the peptide in an animal model does not establish the clinical effect of any one component or of the same combination in people. [1, 2]
Sources
Original works cited in this article. Links open the external record in a new tab.
- 2.Regeneron Pharmaceuticals, Inc. A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity. ClinicalTrials.gov (publication 2024-03-07, record updated 2026-09-01). (opens in a new tab)
clinicaltrials.gov↩ Back to text
